Laurus Labs has informed the stock exchanges that its pharmaceutical formulations and marketing partner Natco Pharma has launched the generic version of Sofosbuvir 400 mg/Velpatasvir 100 mg fixed dose combination in India based on an API supplied by the company. This is part of an agreement between the company and Natco Pharma, wherein the net profit after the sale of this Hepatitis C-related product is shared by the companies.